- Home
- PSBD vs ALLO Comparison
PSBD vs ALLO Comparison
Compare PSBD & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSBD
- ALLO
- Stock Information
- Founded
- PSBD 2009
- ALLO 2017
- Country
- PSBD United States
- ALLO United States
- Employees
- PSBD N/A
- ALLO N/A
- Industry
- PSBD
- ALLO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PSBD
- ALLO Health Care
- Exchange
- PSBD Nasdaq
- ALLO Nasdaq
- Market Cap
- PSBD 452.3M
- ALLO 371.8M
- IPO Year
- PSBD 2024
- ALLO 2018
- Fundamental
- Price
- PSBD $13.81
- ALLO $1.35
- Analyst Decision
- PSBD Buy
- ALLO Strong Buy
- Analyst Count
- PSBD 4
- ALLO 9
- Target Price
- PSBD $14.13
- ALLO $8.44
- AVG Volume (30 Days)
- PSBD 47.7K
- ALLO 4.2M
- Earning Date
- PSBD 05-07-2025
- ALLO 05-13-2025
- Dividend Yield
- PSBD 12.27%
- ALLO N/A
- EPS Growth
- PSBD N/A
- ALLO N/A
- EPS
- PSBD N/A
- ALLO N/A
- Revenue
- PSBD N/A
- ALLO N/A
- Revenue This Year
- PSBD N/A
- ALLO N/A
- Revenue Next Year
- PSBD N/A
- ALLO $10.02
- P/E Ratio
- PSBD N/A
- ALLO N/A
- Revenue Growth
- PSBD N/A
- ALLO N/A
- 52 Week Low
- PSBD $11.51
- ALLO $0.86
- 52 Week High
- PSBD $16.85
- ALLO $3.78
- Technical
- Relative Strength Index (RSI)
- PSBD 55.61
- ALLO 56.21
- Support Level
- PSBD $13.69
- ALLO $1.10
- Resistance Level
- PSBD $14.22
- ALLO $1.15
- Average True Range (ATR)
- PSBD 0.44
- ALLO 0.11
- MACD
- PSBD 0.03
- ALLO 0.04
- Stochastic Oscillator
- PSBD 51.27
- ALLO 96.08
About PSBD Palmer Square Capital BDC Inc.
Palmer Square Capital BDC Inc is a financial services company that lends to and invests in corporate debt securities of companies, including small to large private U.S. companies. Their investment objective is to maximize total return, comprised of current income and capital appreciation.
About ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.